Cargando…

Nano chitosan peptide as a potential therapeutic carrier for retinal delivery to treat age-related macular degeneration

PURPOSE: We describe the synthesis and use of an efficient nano carrier molecule for retinal delivery of a nano chitosan peptide that has potential application for treating age-related macular degeneration (AMD). We chose serine-threonine-tyrosine as the peptide sequence because it is well known to...

Descripción completa

Detalles Bibliográficos
Autores principales: Jayaraman, Melamangalam S., Bharali, Dhruba J., Sudha, Thangirala, Mousa, Shaker A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Vision 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441154/
https://www.ncbi.nlm.nih.gov/pubmed/22977298
_version_ 1782243230367088640
author Jayaraman, Melamangalam S.
Bharali, Dhruba J.
Sudha, Thangirala
Mousa, Shaker A.
author_facet Jayaraman, Melamangalam S.
Bharali, Dhruba J.
Sudha, Thangirala
Mousa, Shaker A.
author_sort Jayaraman, Melamangalam S.
collection PubMed
description PURPOSE: We describe the synthesis and use of an efficient nano carrier molecule for retinal delivery of a nano chitosan peptide that has potential application for treating age-related macular degeneration (AMD). We chose serine-threonine-tyrosine as the peptide sequence because it is well known to act as a transduction signaling agent within and between retinal pigmented epithelium cells. METHODS: A nanoformulation of a water-soluble chitosan conjugated with a peptide (serine-threonine-tyrosine) was synthesized by a method developed in our laboratory and characterized with dynamic light scattering, zeta potential, transmission electron microscopy, nuclear magnetic resonance, and Fourier transform infrared spectroscopy. The in vitro efficacy of the formulation was evaluated in retinal cells with confocal microscopy by studying the formulation’s action on tyrosine kinase activity. RESULTS: The conjugated nano chitosan peptide showed evidence of tyrosine kinase activity as seen by fluorescent signals under confocal microscopy, while nano chitosan or peptide alone did not show such activity. CONCLUSIONS: Conjugated nano chitosan peptide may promote binding and engulfment. This molecule is an excellent carrier for retinal drug delivery and has the potential to treat age-related macular degeneration.
format Online
Article
Text
id pubmed-3441154
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Molecular Vision
record_format MEDLINE/PubMed
spelling pubmed-34411542012-09-13 Nano chitosan peptide as a potential therapeutic carrier for retinal delivery to treat age-related macular degeneration Jayaraman, Melamangalam S. Bharali, Dhruba J. Sudha, Thangirala Mousa, Shaker A. Mol Vis Research Article PURPOSE: We describe the synthesis and use of an efficient nano carrier molecule for retinal delivery of a nano chitosan peptide that has potential application for treating age-related macular degeneration (AMD). We chose serine-threonine-tyrosine as the peptide sequence because it is well known to act as a transduction signaling agent within and between retinal pigmented epithelium cells. METHODS: A nanoformulation of a water-soluble chitosan conjugated with a peptide (serine-threonine-tyrosine) was synthesized by a method developed in our laboratory and characterized with dynamic light scattering, zeta potential, transmission electron microscopy, nuclear magnetic resonance, and Fourier transform infrared spectroscopy. The in vitro efficacy of the formulation was evaluated in retinal cells with confocal microscopy by studying the formulation’s action on tyrosine kinase activity. RESULTS: The conjugated nano chitosan peptide showed evidence of tyrosine kinase activity as seen by fluorescent signals under confocal microscopy, while nano chitosan or peptide alone did not show such activity. CONCLUSIONS: Conjugated nano chitosan peptide may promote binding and engulfment. This molecule is an excellent carrier for retinal drug delivery and has the potential to treat age-related macular degeneration. Molecular Vision 2012-09-03 /pmc/articles/PMC3441154/ /pubmed/22977298 Text en Copyright © 2012 Molecular Vision. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Jayaraman, Melamangalam S.
Bharali, Dhruba J.
Sudha, Thangirala
Mousa, Shaker A.
Nano chitosan peptide as a potential therapeutic carrier for retinal delivery to treat age-related macular degeneration
title Nano chitosan peptide as a potential therapeutic carrier for retinal delivery to treat age-related macular degeneration
title_full Nano chitosan peptide as a potential therapeutic carrier for retinal delivery to treat age-related macular degeneration
title_fullStr Nano chitosan peptide as a potential therapeutic carrier for retinal delivery to treat age-related macular degeneration
title_full_unstemmed Nano chitosan peptide as a potential therapeutic carrier for retinal delivery to treat age-related macular degeneration
title_short Nano chitosan peptide as a potential therapeutic carrier for retinal delivery to treat age-related macular degeneration
title_sort nano chitosan peptide as a potential therapeutic carrier for retinal delivery to treat age-related macular degeneration
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441154/
https://www.ncbi.nlm.nih.gov/pubmed/22977298
work_keys_str_mv AT jayaramanmelamangalams nanochitosanpeptideasapotentialtherapeuticcarrierforretinaldeliverytotreatagerelatedmaculardegeneration
AT bharalidhrubaj nanochitosanpeptideasapotentialtherapeuticcarrierforretinaldeliverytotreatagerelatedmaculardegeneration
AT sudhathangirala nanochitosanpeptideasapotentialtherapeuticcarrierforretinaldeliverytotreatagerelatedmaculardegeneration
AT mousashakera nanochitosanpeptideasapotentialtherapeuticcarrierforretinaldeliverytotreatagerelatedmaculardegeneration